Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
During a panel discussion at the Behavioral Health Tech conference, experts shared the promise psychedelic medicines hold for mental health and why employers may want to consider offering them as a workplace benefit.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there's still a way forward for psychedelic medicines, experts said at HLTH.
In our eagerness for innovation, there's a risk that we ignore existing effective, readily-available treatments.
AbbVie’s alliance with Gilgamesh Pharmaceuticals is pursuing next-generation psychiatric medications. The companies aim to bring patients drugs that offer the benefit of psychedelics but with a better side effect profile.
Research shows that an average of 17.5 veterans die by suicide each day. At ViVE 2024, Shereef Elnahal, the U.S. Department of Veterans Affairs’ under secretary for health, declared that even one veteran dying by suicide is too many — and promised that the VA is pursuing partnerships aimed at addressing this harrowing problem.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Psychedelic-assisted therapy is currently used to treat severe mental health conditions. But there is evidence it could help with prevention as well, and more research needs to be done on this, said Sherry Rais, CEO and co-founder of Enthea.
Despite ketamine-assisted therapy being approved for treating several mental health conditions, it's generally not covered by insurance or employers. Though that likely won't always be the case, as psychedelics gather more research and employers notice the benefits for their workplaces.
Enthea, a benefit plan administrator, works with self-insured employers to provide insurance coverage for psychedelic-assisted therapy. The company has gained $2 million in seed funding, led by Tabula Rasa Ventures. With the money, it is planning a nationwide rollout.